Ceftolozane-Tazobactam Treatment Shows Higher Clinical Success For Invasive Infections Attributable To MDR P. Aeruginosa, Study Finds

Infectious Disease Advisor (2/24) reports, “Treatment with ceftolozane-tazobactam vs ceftazidime-avibactam resulted in increased clinical success [for] invasive infections attributable to multidrug-resistant (MDR) Pseudomonas aeruginosa.” According to the study, “adults with microbiologically confirmed MDR P aeruginosa pneumonia or bacteremia who received either ceftolozane-tazobactam or ceftazidime-avibactam were matched 1:1 within each study site by infection type, illness severity, and time to treatment initiation. The primary outcome was clinical success, which was defined as survival, resolution of signs and symptoms, completion of treatment course, and the absence of recurrent infection at 30 days.” The study was published in The Lancet Infectious Diseases.